USFDA issues 11 observations to Ipca Labs Ratlam facility
Advertisement
Ratlam: Ipca Laboratories Limited has announced that the Company has received eleven observations from the United States Food and Drug Administration (USFDA) after an inspection at the Company’s APIs manufacturing facility situated at Ratlam, Madhya Pradesh.
The inspection was held from 5th June, 2023 to 13th June, 2023.
"At the conclusion of the inspection, the US FDA issued a Form 483 with 11 (eleven) observations," the Company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.